Companies › Y-mAbs Therapeutics
1 active drug program in 24 registered trials: 19 Phase 2, 5 Phase 1; Neurology, Oncology; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sargramostim Granulocyte-macrophage colony-stimulating factor receptor agonist | CSF2RA, CSF2RB | Phase 2 | Neuroblastoma; Bilateral Breast Carcinoma; Neuroblastoma Recurrent; Alzheimer Disease … | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03012100 | Sargramostim | Phase 2 | Bilateral Breast Carcinoma | Oncology | Feb 2025 |
| NCT05754684 | Sargramostim | Phase 2 | Neuroblastoma Recurrent | Oncology | Dec 2025 |
| NCT04902703 | Sargramostim | Phase 2 | Alzheimer Disease | Neurology | Nov 2026 |
| NCT07267234 | Sargramostim | Phase 2 | Solid Cancer | Oncology | Dec 2026 |
| NCT01757626 | Sargramostim | Phase 1 | Neuroblastoma | Oncology | Dec 2026 |
| NCT04237623 | Sargramostim | Phase 2 | Transplant-Related Hematologic Malignancy | Oncology | Dec 2026 |
| NCT06173219 | Sargramostim | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT05817214 | Sargramostim | Phase 2 | Cervical Cancer | Oncology | Feb 2027 |
| NCT01134614 | Sargramostim | Phase 2 | Advanced Melanoma | Oncology | Mar 2027 |
| NCT00669734 | Sargramostim | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma | Oncology | Apr 2027 |
| NCT07078604 | Sargramostim | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | Oncology | Apr 2027 |
| NCT05344209 | Sargramostim | Phase 2 | Oncology | Oncology | Jul 2027 |
| NCT02502786 | Sargramostim | Phase 2 | Recurrent Osteosarcoma | Oncology | Jul 2027 |
| NCT04385277 | Sargramostim | Phase 2 | Ganglioneuroblastoma, Nodular | Oncology | Sep 2027 |
| NCT05242965 | Sargramostim | Phase 2 | Lung Non-Small Cell Carcinoma | Oncology | Nov 2027 |
| NCT03600350 | Sargramostim | Phase 2 | Prostate Cancer | Oncology | Dec 2027 |
| NCT06651853 | Sargramostim | Phase 2 | Diffuse Large B-cell Lymphoma | Oncology | Dec 2027 |
| NCT03363373 | Sargramostim | Phase 2 | Neuroblastoma | Oncology | Apr 2028 |
| NCT07537400 | Sargramostim | Phase 2 | High-Risk Neuroblastoma | Oncology | Jun 2028 |
| NCT06799026 | Sargramostim | Phase 1 | Multiple Myeloma | Oncology | Sep 2028 |
| NCT06528496 | Sargramostim | Phase 2 | High-risk Neuroblastoma | Oncology | Jul 2029 |
| NCT07749365 | Sargramostim | Phase 2 | DLBCL - Diffuse Large B Cell Lymphoma | Oncology | Dec 2029 |
| NCT06626516 | Sargramostim | Phase 1 | Metastatic Uveal Melanoma | Oncology | Oct 2030 |
| NCT02339571 | Sargramostim | Phase 2 | Stage III Cutaneous Melanoma AJCC v7 | Oncology | Jun 2033 |
–
CytoDyn CatalYm Alethia Biotherapeutics Abcuro Solstice Oncology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.